Atlas Trials

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Clinical trial NCT03617731 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03617731
Sponsor
University of Heidelberg Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2018-10-18
Primary completion
2028-06-01
Enrollment
662

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.